Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.6%

3 terminated/withdrawn out of 17 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

35%

6 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 4
6(54.5%)
Phase 1
2(18.2%)
Phase 2
2(18.2%)
N/A
1(9.1%)
11Total
Phase 4(6)
Phase 1(2)
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT06249555Recruiting

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Role: lead

NCT04259138Phase 4Active Not Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis

Role: lead

NCT07363044Not ApplicableRecruiting

A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

Role: lead

NCT06257706Phase 4Recruiting

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Role: lead

NCT06670638Recruiting

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

Role: lead

NCT06997965Phase 4Not Yet Recruiting

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

Role: lead

NCT06363383Phase 1Completed

A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants

Role: collaborator

NCT05928039Phase 4Recruiting

PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Role: collaborator

NCT03261206Phase 4Active Not Recruiting

Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Role: lead

NCT03765450Active Not Recruiting

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

Role: lead

NCT05542355Phase 1Terminated

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Role: collaborator

NCT04847739Phase 2Active Not Recruiting

Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

Role: collaborator

NCT06509828Unknown

Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection

Role: collaborator

NCT05252273Suspended

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

Role: lead

NCT04576000Terminated

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Role: lead

NCT01698307Phase 4Completed

Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

Role: lead

NCT01716039Phase 2Terminated

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Role: lead

All 17 trials loaded